This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Li, X.
Right arrow Articles by Drlica, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Li, X.
Right arrow Articles by Drlica, K.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, November 2004, p. 4460-4462, Vol. 48, No. 11
0066-4804/04/$08.00+0     DOI: 10.1128/AAC.48.11.4460-4462.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.

Quinolone-Resistant Haemophilus influenzae: Determination of Mutant Selection Window for Ciprofloxacin, Garenoxacin, Levofloxacin, and Moxifloxacin

Xinying Li,1 Noriel Mariano,2 James J. Rahal,2 Carl M. Urban,2 and Karl Drlica1*

Public Health Research Institute, Newark, New Jersey,1 Infectious Disease Section, New York Hospital Queens, Flushing, and Department of Microbiology and Medicine, Weill Medical College, Cornell University, New York, New York2

Received 12 March 2004/ Returned for modification 26 April 2004/ Accepted 15 July 2004

Stepwise selection of ciprofloxacin-resistant Haemophilus influenzae mutants produced first-, second-, third-, and fourth-step substitutions in GyrA (S84Y), ParC (S84R), GyrA (D88N), and ParC (E88K), respectively. Successive mutations raised the mutant selection window. The wild-type selection window for garenoxacin, levofloxacin, and moxifloxacin was also measured.

* Corresponding author. Mailing address: Public Health Research Institute, 225 Warren St., Newark, NJ 07103. Phone: (973) 854-3360. Fax: (973) 854-3101. E-mail: drlica{at}phri.org.

Antimicrobial Agents and Chemotherapy, November 2004, p. 4460-4462, Vol. 48, No. 11
0066-4804/04/$08.00+0     DOI: 10.1128/AAC.48.11.4460-4462.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Almahmoud, I., Kay, E., Schneider, D., Maurin, M. (2009). Mutational paths towards increased fluoroquinolone resistance in Legionella pneumophila. J Antimicrob Chemother 64: 284-293 [Abstract] [Full Text]  
  • Nakamura, S., Yanagihara, K., Morinaga, Y., Izumikawa, K., Seki, M., Kakeya, H., Yamamoto, Y., Kamihira, S., Kohno, S. (2009). Melting Curve Analysis for Rapid Detection of Topoisomerase Gene Mutations in Haemophilus influenzae. J. Clin. Microbiol. 47: 781-784 [Abstract] [Full Text]  
  • Morgan-Linnell, S. K., Zechiedrich, L. (2007). Contributions of the Combined Effects of Topoisomerase Mutations toward Fluoroquinolone Resistance in Escherichia coli. Antimicrob. Agents Chemother. 51: 4205-4208 [Abstract] [Full Text]  
  • Wetzstein, H.-G. (2005). Comparative Mutant Prevention Concentrations of Pradofloxacin and Other Veterinary Fluoroquinolones Indicate Differing Potentials in Preventing Selection of Resistance. Antimicrob. Agents Chemother. 49: 4166-4173 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»